Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar Candidate FYB202
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- Testing of comparable pharmacokinetics, safety, and tolerability of FYB202 with reference drug Stelara?*
- Dosing of study subjects started